Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.
about
Limited Efficacy of Antibacterial Vaccination Against Secondary Serotype 3 Pneumococcal Pneumonia Following Influenza Infection.Helper T cell epitope-mapping reveals MHC-peptide binding affinities that correlate with T helper cell responses to pneumococcal surface protein A.Gamma interferon and monophosphoryl lipid A-trehalose dicorynomycolate are efficient adjuvants for Mycobacterium tuberculosis multivalent acellular vaccine.Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines.Intranasal interleukin-12 treatment for protection against respiratory infection with the Francisella tularensis live vaccine strain.Potential role for mucosally active vaccines against pneumococcal pneumoniaDifferential PsaA-, PspA-, PspC-, and PdB-specific immune responses in a mouse model of pneumococcal carriage.Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease.Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives.Controlling invasive pneumococcal disease: is vaccination of at-risk groups sufficient?Dectin-2-dependent NKT cell activation and serotype-specific antibody production in mice immunized with pneumococcal polysaccharide vaccine.Innate endogenous adjuvants prime to desirable immune responses via mucosal routesInactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.Immunization with recombinant Sao protein confers protection against Streptococcus suis infection.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyIdentification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia.Intranasal vaccination of infant mice induces protective immunity in the absence of nasal-associated lymphoid tissue.Mouse models for the study of mucosal vaccination against otitis media.Enhancement of adaptive immunity to Neisseria gonorrhoeae by local intravaginal administration of microencapsulated interleukin 12.Mucosal vaccination against bacterial respiratory infections.Is intranasal vaccination a feasible solution for tuberculosis?Dendritic cell-targeting DNA-based mucosal adjuvants for the development of mucosal vaccinesInterleukin-12 as an adjuvant for induction of protective antibody responses.Combination adjuvants: the next generation of adjuvants?Current adjuvants and new perspectives in vaccine formulation.Cytokines: the future of intranasal vaccine adjuvants.Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.Can mucosal adjuvants contribute to the induction of immunological memory induced via unconjugated T-cell-independent antigens?An overview of adjuvant formulations and delivery systems.Recent advances in vaccine delivery.Utilization of cholera toxin B as a mucosal adjuvant elicits antibody-mediated protection against S. pneumoniae infection in mice.Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs.Induction of in vivo antipolysaccharide immunoglobulin responses to intact Streptococcus pneumoniae is more heavily dependent on Btk-mediated B-cell receptor signaling than antiprotein responses.Serotype-specific correlates of protection for pneumococcal carriage: an analysis of immunity in 19 countries.IL-12 as an adjuvant for the enhancement of protective humoral immunity.
P2860
Q30204865-96EDF985-4D83-466B-91BB-EA351B2E6246Q33535951-9B585267-20C1-449B-8371-E7578E960CB1Q33558303-18CA806E-AA39-4524-A79C-29256EF8629FQ33676505-F8CBC221-6504-41C0-8B9D-5913998309C7Q33769426-0D3E0C16-DBA4-4FF1-B985-B7A169B8AB4CQ33792681-2CFA3B0E-1A77-42E5-9EFC-F18CF5FF4C8DQ33798317-D2E67596-362F-4DAA-BBEE-8DFEB822601CQ33999595-775B59FD-9F16-4EC7-9D49-D13856974AADQ34309830-8E640B21-8DD7-4797-97D0-10C17251C887Q34569275-3918DCB2-1516-4E1C-971A-465ECA3F6F93Q35036583-3E68580D-C771-4FA1-B2BE-BCCACD4C4CAEQ35143128-CD2364AA-23D6-4DE9-9B4A-66B4B5596B0AQ35784151-457846DF-1DD7-42F5-A3F8-E70B4C151FFEQ35953762-3D833F80-AD20-4986-9B64-63989630E649Q36097153-A27FAB11-25D5-4DF8-AA97-901359AC86F4Q36116250-B797BA78-E170-4520-AFB6-917F1539BB35Q36191199-BE6E7249-8F81-4ECE-B149-D304B5E334C5Q36571911-1735782D-EDD6-428D-B3AF-B42B806A1B95Q37093093-C1F0D440-0039-4E4F-A652-BE2D1108CFCAQ37272314-8C2F16FD-3872-47EF-8E16-BD05BFFE398BQ37290114-DC07EFFA-7C0E-42E7-ADF5-F2CB2499DA93Q37316013-633A30CD-C104-4EE5-AA85-B14B1DE9B281Q37590337-880132FF-7D00-4303-993B-AE4B63D98180Q37774770-7AEAA9CD-2A3E-47AB-BF31-9EE2B45863CAQ37821483-13723A30-E375-44C6-9077-09B40E966862Q37909424-4083F9D8-D1EC-4547-95E5-5D771C018BDBQ37914007-5D8F98D0-3113-438A-A008-7E9793A3CB5CQ37914449-9081D5D1-E1FD-4CE4-BA96-E82952E910DDQ38013202-03754284-F608-42EA-9607-F21AC32D2943Q38126953-7452FF24-512D-4A0B-B9F7-25C8B2DF5FB4Q38669255-82ECD27B-FA9C-4F2E-A6AB-73F5D257351FQ40277871-C35E9963-C111-4219-8741-48900B8EE2CAQ42116037-47587F4F-7DEF-4215-8A60-FFFBD9C67B05Q43196580-8E355EDF-B487-468C-8495-D8645F71AEA2Q46144154-369C9196-68C6-4A1B-8E80-004C5A1B26D4Q47933660-C8E0D83F-3AAE-465E-9DF6-E13DA33D9786
P2860
Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Increased protection against p ...... e vaccine plus interleukin-12.
@ast
Increased protection against p ...... e vaccine plus interleukin-12.
@en
type
label
Increased protection against p ...... e vaccine plus interleukin-12.
@ast
Increased protection against p ...... e vaccine plus interleukin-12.
@en
prefLabel
Increased protection against p ...... e vaccine plus interleukin-12.
@ast
Increased protection against p ...... e vaccine plus interleukin-12.
@en
P2093
P2860
P1476
Increased protection against p ...... e vaccine plus interleukin-12.
@en
P2093
David E Briles
Dennis W Metzger
Joyce M Lynch
P2860
P304
P356
10.1128/IAI.71.8.4780-4788.2003
P407
P577
2003-08-01T00:00:00Z